New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
February 12, 2013
06:58 EDTVNDAVanda Pharmaceuticals to submit Tasimelteon NDA in mid-2013
In December 2012 and January 2013, Vanda announced positive results for two Phase III studies for tasimelteon in the treatment of Non-24. The SET Phase III study demonstrated that tasimelteon was able to entrain the master body clock as measured by melatonin and cortisol circadian rhythms. Vanda plans to submit an NDA to the FDA in mid-2013. Vanda will meet with the FDA in Q1 of 2013 for a pre-NDA meeting on tasimelteon in the treatment of patients with Non-24.Vanda has decided to discontinue all activities related to the MDD indication. In January, Vanda announced that the MAGELLAN Phase IIb/III clinical study in MDD did not meet the primary endpoint of a change from baseline in the Hamilton Depression Scale after 8 weeks of treatment as compared to placebo. Vanda has formally appealed the EMA's negative opinion for Fanaptum and requested a re-examination of the decision by the EMA's Committee for Medicinal Product for Human Use.
News For VNDA From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
October 29, 2014
09:01 EDTVNDAVanda 4M share Spot Secondary priced at $11.60
Subscribe for More Information
October 28, 2014
16:02 EDTVNDAVanda files to sell common stock, no amount given
Jefferies LLC and Piper Jaffray & Co. are acting as the joint book-running managers for the offering.
08:05 EDTVNDAPressure on Vanda unwarranted, says JMP Securities
After Vanda reported stronger than expected Q3 results, JMP Securities thinks the pressure on the stock is disconnected from the company's strong Helioz launch. The firm keeps a $30 price target and Outperform rating on the shares.
October 27, 2014
09:14 EDTVNDAOn The Fly: Pre-market Movers
Subscribe for More Information
07:18 EDTVNDAVanda reports Q3 total operating expenses $16.2M compared to $14.1M a year ago
07:17 EDTVNDAVanda cuts FY14 operating expenses to $105M-$110M from $110M-$120M
Subscribe for More Information
07:17 EDTVNDAVanda reports Q3 Hetlioz US sales grew to $5.2M
Subscribe for More Information
07:16 EDTVNDAVanda reports Q3 EPS (4c), consensus (39c)
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use